Novartis Global Pipeline

Benefitting from our continued focus on innovation, Novartis has one of the industry’s most competitive pipelines with more than 200 projects in clinical development.

Many of these projects, which include new molecular entities as well as additional indications and different formulations for marketed products, are for medicines that could significantly advance treatment standards for patients worldwide. This table provides an overview of selected projects in development.

For a detailed review of selected projects in confirmatory development, download the complete Novartis Pipeline (PDF 0.1 MB), as of December 31, 2020.

Please note: the Novartis Pipeline data is updated quarterly.

Displaying 81 - 90 of 167 result(s)
Supplementary Indication

KJX839

Leqvio®

Secondary prevention of cardiovascular events in patients with elevated levels of LDLC (CVRR-LDLC)

Cardiovascular, Renal & Metabolism

Phase 3

>=2025

siRNA (PCSK9)

KJX839

Leqvio®

Hyperlipidemia

Cardiovascular, Renal & Metabolism

Registration

siRNA (PCSK9)

LAM320

Lamprene®

Tuberculosis

Global Health

Registration

2022

SMPD1 Inhibitor (Mycobacterial DNA binding)

Supplementary Indication

LCZ696

Entresto®

Post Acute myocardial infarction (Post-AMI)

Cardiovascular, Renal & Metabolism

Phase 3

2021

Angiotensin receptor/neprilysin inhibitor

LCZ696

Entresto®

Chronic heart failure with preserved ejection fraction (HFpEF)

Cardiovascular, Renal & Metabolism

Registration

Angiotensin receptor/neprilysin inhibitor

Supplementary Indication

LCZ696

Entresto® EUa

Pediatric HF

Cardiovascular, Renal & Metabolism

Phase 3

2022

Angiotensin receptor/neprilysin inhibitor

LCZ696

Entresto®

Non-obstructive hypertrophic cardiomyopathy (nHCM)

Cardiovascular, Renal & Metabolism

Phase 2

>=2025

Angiotensin receptor/neprilysin inhibitor, NEP, AGTR1, AGTR2 Inhibitor

Supplementary Indication

LEE011

Kisqali®

Hormone receptor-positive, HER2-negative breast cancer (HR+, HER2- BC) (adjuvant)

Oncology

Phase 3

2023

CDK4/6 inhibitor

Lead Indication

LHC165

LHC165 + spartalizumab

Solid tumors

Oncology

Phase 1

TLR7 Agonist

Lead Indication

LJC242

tropifexor,cenicriviroc (in fixed-dose combination)

Non-alcoholic steatohepatitis (NASH) (combos)

Immunology, Hepatology and Dermatology

Phase 2

>=2025

FXR agonist, CCR2/5 inhibitor

Legend

Combination abbreviations:
fulv fulvestrant
tmx tamoxifen
gsn goserelin
NSAI Non-steroidal aromatase inhibitor
Taf Tafinlar® (dabrafenib)
Mek Mekinist® (trametinib)
a EU filing, approved in US.
b US filing, approved in EU.
c US filing, submitted in EU.
d US pending submission, approved in EU
e EU filing, submitted in US.

Disclaimer

This information was factually accurate on the date it was published. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information on this page as current or accurate after its publication date. For the latest information on the Novartis' pipeline, readers should visit the News and Investors sections of our website. This information constitutes forward-looking statements relating to Novartis AG's business, including express or implied discussions regarding potential new products, potential new indications for existing products, or regarding potential future revenues from any such products. Such forward-looking statements reflect the current views of Novartis AG regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that any new products will be approved for sale in any market, or that any new indications will be approved for existing products in any market, or that such products will achieve any particular revenue levels.

In particular, management's expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays or government regulation generally; the Novartis Group's ability to obtain or maintain patent or other proprietary intellectual property protection, including the uncertainties involved in the US litigation process; competition in general; government, industry, and general public pricing and other political pressures; and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.